# Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers

> **NCT02262598** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 30 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Telmisartan
- **DRUG:** Hydrochlorthiazide (HCTZ)
- **DRUG:** Telmisartan/HCTZ fixed dose

## Key facts

- **NCT ID:** NCT02262598
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** 2004-10
- **Final completion:** —
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2014-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02262598

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02262598, "Bioequivalence of Telmisartan / HCTZ of Fixed Dose Combination Compared to Its Monocomponents in Healthy Male Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02262598. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*